The Study
Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
This study found that a blood test for p-tau217 can tell us if someone is likely to have amyloid plaques in their brain — kind of like a warning sign for Alzheimer’s. But it doesn’t prove the blood test causes the plaques or that everyone with high levels will get dementia — it just shows they often go together.
Analysis score
Maximum 44 for a cross-sectional study.
Where the score came from
Scientists tested a blood marker called p-tau217 in older people with brain blood vessel problems to see if it could tell if they had Alzheimer's plaques.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 544 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This means a simple blood test could help doctors avoid expensive brain scans for most people — only 1 in 10 would need further testing.
- 2A p-tau217 level above 0.471 pg/mL correctly identified Alzheimer's plaques in 82% of cases (AUC = 0.923) and predicted 0.83 faster points of memory loss per year.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Alzheimer's & Dementia
Year
2025
Authors
J. Chong, S. Hilal, B. Tan, N. Venketasubramanian, M. Schöll, H. Zetterberg, K. Blennow, N. Ashton, Christopher P Chen, Mitchell K. P. Lai
Related Content
Claims (6)
In older adults with cerebrovascular disease, higher levels of p-tau217 in the blood are linked to a faster rate of cognitive decline measured by the MMSE test over 2.57 years.
In a group of 215 older adults with high cerebrovascular disease burden, the blood biomarker p-tau217 correctly identified amyloid-beta positivity on PET scans more accurately than clinical evaluations, other blood biomarkers, or combined clinical models.
In people with significant cerebrovascular disease, the blood biomarker p-tau217 accurately identifies amyloid-beta positivity with an AUC of 0.929, while GFAP is less accurate with an AUC of 0.779.
Blood levels of p-tau217 can identify the presence of amyloid-beta plaques in the brain with 95% to 97% accuracy, allowing Alzheimer's pathology to be detected decades before symptoms appear.
In adults aged approximately 76 with significant blood vessel disease in the brain, a blood biomarker called p-tau217 above 0.471 pg/mL consistently correlates with the presence of amyloid-beta plaques detected by PET imaging, with 82% accuracy in identifying those with amyloid pathology.
Using specific plasma p-tau217 thresholds to classify Alzheimer's disease risk reduces the number of patients needing amyloid PET scans from 40–57% to 10%, compared to standard clinical assessments.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.